450 results about "Antigenic protein" patented technology

The invention relates to a nano antibody targeting cadherin 17 and application thereof, and relates to the technical field of immunology and molecular biology, the amino acid sequence of a complementary determining region of the nano antibody targeting cadherin 17 comprises CDR1 shown as any one of SEQ ID NO: 21-32, CDR2 shown as any one of SEQ ID NO: 34-45, and CDR3 shown as any one of SEQ ID NO: 47-58. According to the invention, an alpaca immune phage display library is constructed, a series of nano antibody molecules targeting cadherin 17 (CDH17) are screened from the alpaca immune phage display library, and functions and applications of the nano antibody are verified at various levels of CDH17 antigen protein, CDH17 target cells, CDH17 CAR-T cells and the like.

The invention belongs to the field of animal vaccines, and particularly relates to a multi-epitope fusion protein aiming at multi-serotype laisseria parasuis antigen and application. The applicant carries out proteomics analysis on four clinical isolated strains of serotypes 4, 5 and 13 of the parasuis leather serotype 4, 5 and 13 with high toxicity and good immunogenicity, and eight antigen proteins are screened out of the four clinical isolated strains of the serotypes 4, 5 and 13 of the parasuis leather serotype 4, 5 and 13. And further analyzing the screened eight antigen proteins to finally obtain the antigen multi-epitope fusion protein with immunogenicity capable of recognizing three serotypes. When the fusion protein is used as a vaccine, the protection rate of clinically separated piglets infected with a serum type 4 strain HB04, a serum type 5 strain SJZ05 and a serum type 13 strain GD20 reaches 100%.

The invention discloses a Graisseria parasuis three-component subunit vaccine and a preparation method thereof, and belongs to the technical field of biology. The vaccine comprises three kinds of antigen proteins of the Gleisseria parasuis in an immunizing dose and a pharmaceutically acceptable adjuvant, and the amino acid sequences of the three kinds of antigen proteins are respectively shown as SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3. The invention further discloses a preparation method of the vaccine. The three-component subunit vaccine provided by the invention has cross protection force on infection of type-4 and type-5 Graisseria parasuis, has an excellent immune protection effect, and is expected to play a better role in prevention and control of infectious diseases caused by the Graisseria parasuis.

The invention belongs to the technical field of biology, and discloses a stable protective agent, a cell antigen dry sheet and a preparation method and application of the dry sheet, the stable protective agent comprises glycerin with the volume fraction being 0.4%, gelatin with the mass volume fraction being 0.1%, EDTA with the mass volume fraction being 0.1 mM, trehalose with the mass volume fraction being 0.03% and resveratrol with the mass volume fraction being 100 [mu] M. The stable protective agent is adopted for preparing the cell antigen dry sheet, and the cell antigen dry sheet is applied to CBA detection. The stable protective agent has good permeability, can penetrate through cell membranes to enter cells, provides a protection effect inside and outside the cells, has moisture retention and oxidation resistance, can prevent cell deformation and cell fixing layer shedding, and can well maintain the stability and reliability of antigen proteins, and the prepared cell antigen dry sheet can be stored for a long time, and has a good application prospect. The antigenicity of a membrane signal index is not damaged. When a positive sample is detected, obvious green fluorescence cells can be seen, red fluorescence quenching is avoided, and co-localization of red fluorescence and green fluorescence can be observed conveniently.

The invention discloses a method for displaying foreign protein by utilizing salmonella and application of the method, and belongs to the technical field of biological medicine. According to the invention, the SpyCatcher and an outer membrane protein Lpp-OmpA gene are fused and are expressed in salmonella, a recombinant strain is constructed, and the SpyCatcher is displayed on the surface of bacteria; the foreign protein gene and the SpyTag gene are fused and subjected to prokaryotic expression purification, and recombinant foreign protein is obtained; after the recombinant foreign protein and the recombinant salmonella are incubated, the foreign protein can be anchored on the surface of the salmonella through a SpyCatcher-SpyTag covalent bond. When the foreign protein is an antigen protein, the foreign protein is displayed on the surface of the attenuated bacterial vector, and a live vector vaccine can be prepared. The invention provides a novel universal antigen display method, overcomes the limitation of the traditional antigen display method on the protein size and conformation, and has a good application prospect in live vector vaccine construction.

The invention discloses a porcine epidemic diarrhea virus antigen fusion protein, a coding gene and a porcine epidemic diarrhea vaccine prepared from the porcine epidemic diarrhea virus antigen fusion protein. The method comprises the following steps: screening to obtain a homosensory sequence of the spike protein of the porcine epidemic diarrhea virus, and fusing the homosensory sequence with a monomeric porcine ferritin heavy chain subunit to obtain an antigen fusion protein; in order to improve the expression quantity or the titer of the antigen fusion protein, the obtained antigen fusion protein is subjected to sequence optimization and then subjected to single-site or multi-site mutation, and the expression quantity and the titer of the obtained mutant are remarkably improved. According to the invention, a recombinant protein is expressed by using a silkworm or AcMNPV-insect cell and other eukaryotic expression systems to obtain a self-assembled ferritin nanoparticle antigen for displaying an S protein antigen protein on the surface of a cage structure of porcine ferritin, and a vaccine prepared from the prepared nanoparticle antigen can induce a widely neutralized anti-porcine epidemic diarrhea virus antibody; the porcine epidemic diarrhea virus vaccine has the potential of becoming a universal porcine epidemic diarrhea virus vaccine with cross immune efficacy.

Provided herein are isolated polynucleotides encoding a polypeptide comprising an antigen protein fused to a signal sequence and a transmembrane domain, and optionally fused to a ferritin. Also provided herein are isolated polynucleotides encoding alphaviral non-structural proteins nsp1, nsp2, nsp3, and nsp4 and polypeptides comprising an antigen protein fused to a signal sequence and a transmembrane domain, and optionally fused to a ferritin. The antigen may be influenza. Polynucleotides, such as RNAs, can be used as vaccines against influenza infection.

The present invention belongs to the technical field of microorganisms, and provides a Bacillus subtilis FNFH_BS08 and use thereof. On the one hand, the present invention provides a Bacillus subtilis FNFH_B808, on the other hand, the present invention provides use of the Bacillus subtilis FNFH_BS08. The Bacillus subtilis FNFH_BS08 of the present invention can efficiently degrade main antigen proteins and non-starch polysaccharides in soybean meal by secreting highly active carbohydrate enzymes and proteases, thus improving the overall nutritional parameters of the soybean meal, improving the nutritional value of the soybean meal, and reaching a leading level in the field of fermentation of soybean meal by microorganisms.

The invention provides a construction method and application of a high-efficiency expression system based on a Seali forest virus replicon. The method comprises the following steps: constructing a saRNA system for expressing a reporter gene; constructing to obtain replicase providing plasmids in the taRNA system; constructing to obtain an antigen providing plasmid in the taRNA system; the method comprises the following steps: respectively linearizing pSFV-CMV-T7-X, pSFV-CMV-T7-TR-X and pSFV-CMV-T7-replicase, and then carrying out in vitro transcription to prepare mRNA (Messenger Ribonucleic Acid); transfecting the prepared mRNA into a host eukaryotic cell for expression according to a certain proportion to obtain an antigen protein; and detecting the antigen protein to evaluate the expression efficiency of the saRNA and taRNA system based on the SFV replicon. According to the self-amplification DNA and RNA vaccine based on the virus replicon, the development period can be shortened, and the vaccine antigen can be expressed at a high level.

The invention relates to an antibody detection kit for neuroparatoma syndrome and a preparation method of the antibody detection kit. The antibody detection kit for neuroparatoma syndrome comprises an antibody detection strip, a cleaning solution, a buffer solution and an auxiliary agent, wherein the antibody detection strip is a nitrocellulose membrane which is coated with antigen proteins containing Amphiphysin, CV2, GAD65, Hu, PNMA2 (Ma2 / Ta), Recovery, Ri, SOX1, Titin, Tr (DNER), Yo and Zic4. The invention further discloses a detection method of the antibody detection strip. The antibody detection kit disclosed by the invention can be used for simultaneously detecting 12 autoantibodies related to the neuroparatoma syndrome. The design of simultaneous detection of multiple antibodies greatly improves the comprehensiveness of detection, so that multiple possible pathogenic factors can be covered in single detection, the kit can be used for differential diagnosis of suspected neuroparatoma syndrome patients in professional laboratories, and the problem of missed diagnosis caused by single antibody detection is avoided.

The invention provides a genetically engineered bacterial exosome vesicle and application thereof in preparation of a medicine for treating tumors, and comprises a genetically engineered bacterial exosome vesicle Neo-MICBOMVs, and the surface of the genetically engineered bacterial exosome vesicle Neo-MICBOMVs is loaded with a fusion protein composed of a tumor neoantigen protein and an MICB [alpha] 3 structural domain protein. The fusion protein can be used as a vaccine pharmaceutical composition for treating tumors, can be used as a targeting antigen presenting cell, can promote activation of an immune system, can increase immune infiltration in a tumor microenvironment, can inhibit immune escape of tumor cells, and can improve the effect of tumor immunotherapy.

The invention discloses a haemonchus contortus subunit vaccine, and belongs to the field of veterinary vaccines. The subunit vaccine comprises an antigen protein MEP3, an antigen protein AP1, an antigen protein AP8, an antigen protein H11-2, an antigen protein H11-4 and an antigen protein AP5 of galactosylated and modified haemonchus contortus, and the antigen protein MEP3, the antigen protein AP1, the antigen protein AP8, the antigen protein H11-2, the antigen protein H11-4 and the antigen protein AP5 of galactosylated and modified haemonchus contortus. The galactosylation modification of the antigen protein is realized by jointly expressing glycosyl transferase HcGALT of haemonchus contortus and one or more of the proteins in eukaryotic cells. The antigen protein modified by galactosylation in the subunit vaccine is closer to the glycosylation modification of natural protein, and can provide effective immune protection after the goat is infected with haemonchus contortus, and the egg laying rate is reduced by 81.43%. The invention lays a foundation for development of haemonchus contortus subunit vaccines, provides an effective technical means for prevention and treatment of the haemonchus contortus subunit vaccines, and has important application value and popularization prospect.

Provided herein are nucleic acid molecules encoding viral replication proteins and antigenic coronavirus proteins or fragments thereof. Also provided herein are compositions that include nucleic acid molecules encoding viral replication and antigenic proteins, and lipids. Nucleic acid molecules provided herein are useful for inducing immune responses.

The invention discloses a mycoplasma hyopneumoniae multi-antigen fusion protein and a vaccine composition and application thereof, and belongs to the technical field of genetic engineering and vaccines. The fusion protein comprises an escherichia coli heat-labile enterotoxin LTB, a mycoplasma hyopneumoniae antigen protein P97R1, a mycoplasma hyopneumoniae lipoprotein 418 and a mycoplasma hyopneumoniae surface antigen protein P46 from the N terminal to the C terminal in the sequence. The vaccine composition comprises the fusion protein and an adjuvant acceptable in veterinary medicine. A vaccine prepared from the fusion protein has the advantages of higher pertinence and immunogenicity, the cell and humoral immune response level is remarkably improved, and meanwhile, the fusion protein is easy to purify and prepare and suitable for large-scale industrial production.

The present invention relates to the field of veterinary vaccines, and discloses the development and application of a subunit vaccine for porcine contagious pleuropneumonia. The TbpB-C truncated protein and the AdhE whole protein selected in the antigen protein combination of the vaccine of the present invention are highly homologous in all APP serotypes, and are prepared into subunit vaccines that can provide cross protection to porcine actinobacillus pleuropneumoniae of different serotypes, and the protection rates against APP1 type and APP3 type strains are both 100%. The truncated proteins selected in the antigen protein combination of the present invention are successfully expressed in a soluble form after optimization, and are easy to express and purify in large quantities, thereby reducing production costs. The present invention lays a foundation for the development of an efficient, low-cost, broad-spectrum subunit vaccine for porcine contagious pleuropneumonia, and provides an effective technical means for the prevention and treatment of the disease.

The invention belongs to the field of biological detection, and particularly relates to a kit for detecting serum autoantibodies and application of the kit. The kit comprises a standard substance, an elisa plate coated with recombinant antigen protein, an elisa secondary antibody, a developing solution and a reaction stop solution, and the recombinant antigen protein is a recombinant HNRNPA3 antigen protein with a His tag. The kit for detecting the breast cancer, provided by the invention, is high in specificity, can specifically detect the content of the HNRNPA3 autoantibody, and is crucial for early screening and diagnosis of cancers as an auxiliary diagnosis means for the breast cancer with high expression of the HNRNPA3 autoantibody.

Provided herein are nucleic acid molecules encoding viral replication proteins and antigenic coronavirus proteins or fragments thereof. Also provided herein are compositions that include nucleic acid molecules encoding viral replication and antigenic proteins, and lipids. Nucleic acid molecules provided herein are useful for inducing immune responses.

The invention discloses chicken infectious anemia virus-like particles as well as a preparation method and application thereof. The invention discloses a virus-like particle vaccine for preventing chicken infectious anemia. The virus-like particle vaccine comprises VP1 and VP2 proteins of chicken infectious anemia viruses. Chicken infectious anemia VP1 and VP2 proteins are expressed by using a baculovirus expression system, immunoblotting shows that the two proteins are successfully expressed in sf9 cells, electron microscope observation finds that the expressed proteins can be autonomously assembled into complete chicken infectious anemia virus-like particles, and the chicken infectious anemia virus-like particles have a space structure similar to that of an original virus and can be used for preparing chicken infectious anemia virus-like particles. Meanwhile, the virus-like particles have the advantages of high titer, high safety, capability of stimulating humoral immunity and cellular immunity and the like. The preparation method disclosed by the invention is simple, can be used for preparing the antigen protein of the chicken infectious anemia virus on a large scale, is high in expression quantity and short in time consumption, greatly reduces the production cost, and is suitable for large-scale production.

The invention discloses a group of shark nano antibodies targeting infectious subcutaneous and hematopoietic necrosis viruses of prawns and a preparation method of the shark nano antibodies. The amino acid sequence of the nano antibodies is any one amino acid sequence selected from SEQ ID NO.8-14, and the nano antibodies can be used for detecting cp, nsp1 and nsp2 antigen proteins of the infectious subcutaneous and hematopoietic necrosis viruses. The preparation or screening method of the nano antibody comprises the following steps: A, expression and purification of cp, nsp1 and nsp2 antigen proteins; b, constructing a shark natural library and / or a shark immune library; c, assisting in phage rescue, and purifying to obtain a phage library; d, panning a phage library of anti-cp, anti-nsp1 and anti-nsp2 antigen proteins; and E, carrying out phage-ELISA identification and sequencing, and carrying out sequence comparison on the cp nano antibody, the nsp1 nano antibody and the nsp2 nano antibody with different CDR3 region sequences. The nano antibody provided by the invention can specifically recognize infectious subcutaneous and hematopoietic necrosis viruses, can detect whether aquaculture animals and aquaculture feeds in aquaculture water are polluted by viruses or not, and realizes rapid detection.

The invention discloses a swine fever and porcine parvovirus bivalent subunit vaccine and a preparation method thereof. The vaccine comprises a first recombinant protein encoded by a first gene, a second recombinant protein encoded by a second gene and a pharmaceutically acceptable carrier. The first gene has a sequence as shown in SEQ ID NO: 1 or an increased or reduced sequence thereof. And the second gene has a sequence as shown in SEQ ID NO: 2 or an increased or reduced sequence thereof. An antigen E2 protein of a hog cholera virus (CSFV) and a VP2 protein of a porcine parvovirus (PPV) are taken as double targets, a recombinant SC-E2 protein with a SpyCatcher tag and a recombinant ST-VP2 protein with a SpyTag tag are respectively expressed in insect cells through a recombinant baculovirus vector, double-antigen covalent assembly is realized in vitro, and the constructed bivalent subunit vaccine can be used for simultaneously preventing and controlling two epidemic diseases and has a good application prospect. And the vaccine has the advantages of high safety, strong immunogenicity, high prevention and control efficiency, easiness in large-scale production and the like.

The invention discloses a compound preparation, the compound preparation contains bacillus subtilis and lactobacillus casei, the bacillus subtilis is bacillus subtilis, the strain number of the bacillus subtilis is YB-10, the bacillus subtilis is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC NO.21103, and the lactobacillus casei is preserved in the China General Microbiological Culture Collection Center (CGMCC). The lactobacillus casei is lactobacillus casei, the strain number of the lactobacillus casei is TD01, the lactobacillus casei is preserved in the China Center for Type Culture Collection, and the preservation number of the lactobacillus casei is CCTCC NO: M 2022104. The bacillus subtilis YB-10 disclosed by the invention has a very high degradation rate on antigen protein in soybean meal, and can accumulate high-content acid soluble protein under the condition of solid state fermentation; the lactobacillus casei TD01 disclosed by the invention has a very good degradation effect on stachyose and raffinose in soybean meal; an intracellular metabolite obtained after autolysis of the lactobacillus casei TD01 cell has relatively high aminopeptidase activity, and bitter taste caused by accumulation of high acid soluble protein can be effectively removed.

The present invention relates to antigen-binding proteins capable of fully neutralizing snake venom PLA2 neurotoxin lethality, antigen-binding proteins capable of fully neutralizing snake venom short-chain alpha neurotoxin lethality, and oligoclonal antigen-binding mixtures capable of binding to, blocking, or neutralizing PLA2 neurotoxin and short-chain alpha neurotoxin from coral snake venoms. The invention also relates to pharmaceutical compositions, kit of parts and kits for the treatment and diagnosis of snake envenomation.

An amphiphilic polymer LY0016, which has the chemical structure as shown in the following formula (I), a method for preparing same, and the use thereof in the preparation of a pharmaceutical preparation comprising a drug active molecule. The drug active molecule comprises, but is not limited to, a small molecule compound, a peptide analogue, a polypeptide or an antigen, a protein, an antibody and an immunologic adjuvant.

The invention discloses a bispecific antibody which comprises a first protein functional region targeting CD30 and a second protein functional region targeting CD16a, the first protein functional region comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3. The invention also discloses nucleic acid for coding the antibody, a recombinant expression vector, a transformant, a preparation method of the antibody, an antibody drug conjugate, a pharmaceutical composition or a kit containing the antibody drug conjugate, and applications of the nucleic acid, the recombinant expression vector and the transformant in preparation of drugs for preventing and / or treating tumors. The bispecific antibody provided by the invention can effectively activate the NK cells and can effectively target human tumor cell related antigen CD30 protein, mediate the killing activity of the NK cells to target cells, and induce and further enhance the tumor inhibition effect of the NK cells to tumor cells.

The invention discloses a polypeptide drug chimera and a preparation method thereof, and belongs to the technical field of polypeptide drug carriers. The polypeptide drug chimera is constructed by a recognition segment specifically combined with a target protein and a functional polypeptide carrier mediating the target protein to be transferred to lysosome; an antibody is combined with a lysosome signal amino acid sequence, and pathogenic antigen protein is transferred into a lysosome subcellular organelle for degradation through specific combination of the antibody and different antigens.

The invention discloses a Fel D1 and Fel D4 fusion protein and application thereof, the Fel D1 and Fel D4 fusion protein is obtained in a prokaryotic expression mode, the fusion expressed protein greatly simplifies operation procedures in the aspects of inducing protein expression, purification, concentration, immunization and the like, and the economic cost is reduced. According to the preparation method of the egg yolk antibody provided by the invention, the egg yolk antibody obtained through fusion protein immunization laying hens can be subjected to antibody-antigen reaction with Fel D1 and Fel D4 respectively, and the titer of the egg yolk antibody is higher than that of a single antigen protein immunization group and a combined immunization group. The invention further provides a preparation method of the functional cat food, the egg yolk powder is added into the cat food according to a certain proportion, after the cat food is fed for a period of time, the content of Fel D1 and Fel D4 in cat hair and saliva is remarkably reduced, the cat food prepared from the fusion protein egg yolk antibody can resist Fel D1 and Fel D4 at the same time, and the blocking effect is remarkably improved.

The invention provides a BVDV E2 recombinant protein and a preparation method and application thereof, and relates to the technical field of biological antibody preparation and biological detection.The BVDV E2 recombinant protein is obtained from Genebank, the antigen protein gene is expressed and purified and then serves as an antigen to immunize a mouse, and a mouse anti-BVDV antibody is obtained and applied to double-antibody sandwich detection. And detecting the bovine viral diarrhea virus. The invention has the beneficial effects of good stability and high sensitivity.

An anti-BDCA-2 antibody, a preparation method therefor, and a use thereof, relating to the field of antibodies. The preparation method for the anti-BDCA-2 antibody comprises: carrying out ELISA detection and screening on a hybridoma cell culture supernatant and an antigen protein to obtain a positive clone, and subcloning the positive clone to obtain the anti-BDCA-2 antibody. The anti-BDCA-2 antibody comprises a heavy chain and a light chain, wherein a variable region of the heavy chain and a variable region of the light chain are selected from amino acid sequences as shown in SEQ ID NOs: 1-22. The anti-BDCA-2 antibody and related drugs can be used for inhibiting the production of IFN-α by pDCs and preventing the over-activation of the pDCs. The anti-BDCA-2 antibody can effectively inhibit the activation of pDC cells and the production of IFN-α, and has great potential in resisting virus infection and preventing certain autoimmune diseases.

The present application provides a vaccine comprising: 1) a peptide oligomer consisting of 2-8 copies of a bacteriophage T4 fibrin C-terminal polypeptide and one or more antigen proteins; or 2) a coding nucleic acid of item 1) wherein 2-8 copies of the bacteriophage T4 fibrin C-terminal polypeptides in the peptide oligomer are directly linked in series through chemical bonds or each of the bacteriophage T4 fibrin C-terminal polypeptides is linked to each other through a peptide linker, and the peptide oligomer and the antigen protein are directly connected through a chemical bond or connected through a peptide linker. In the bi-T4-virus antigen vaccine platform provided by the invention, the antigen can be subjected to multi-component change, that is, the antigen can form a trimer, so that the use flexibility of the vaccine platform is enhanced, the application range of the vaccine platform is widened, and the bi-T4 structure can enhance the formation of trimer protein and enhance the immune aging.

The invention belongs to the field of biological medicine, and particularly relates to a varicella-zoster virus gB protein mutant and application thereof. According to the gB protein mutant of the varicella-zoster virus, provided by the invention, proline mutation, shearing of N-terminal and C-terminal structural domains, release of electrostatic repulsive force in the protein, mutation of a Frelin enzyme cutting site and the like are carried out in a process of converting a gB protein fusion precursor into a fusion afterbody conformation, so that the gB protein mutant of the varicella-zoster virus is obtained. The conformation before fusion can be stabilized, and the expression quantity and the stability of the antigen protein are improved. As a vaccine component, the mutant has good immunogenicity, activates autoimmunity of animals and plays a role in prevention or treatment of vaccines.